Jpmorgan Chase & CO Cassava Sciences Inc Transaction History

Jpmorgan Chase & CO

$1.51 Trillion
Q3 2025

A detailed history of Jpmorgan Chase & CO transactions in Cassava Sciences Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 565,439 shares of SAVA stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

565,439

Previous 565,439 -0.0%

Holding current value

$1.56 Million

Previous $1.65 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	SELL	$1.85 - $3.41 $415,467 - $765,807	-224,577 Reduced 28.43%	565,439 $1.65 Million
Q1 2025 May 12, 2025	BUY	$1.5 - $3.02 $583,021 - $1.17 Million	388,681 Added 96.85%	790,016 $1.19 Million
Q4 2024 Feb 12, 2025	BUY	$2.29 - $32.18 $835,808 - $11.7 Million	364,982 Added 1003.99%	401,335 $947,000
Q3 2024 Dec 26, 2024	SELL	$9.57 - $35.08 $186,844 - $684,901	-19,524 Reduced 34.94%	36,353 $1.07 Million
Q3 2024 Nov 08, 2024	SELL	$9.57 - $35.08 $186,844 - $684,901	-19,524 Reduced 34.94%	36,353 $1.07 Million
Q2 2024 Dec 26, 2024	BUY	$12.35 - $26.11 $241,121 - $509,771	19,524 Added 53.71%	55,877 $690,000
Q2 2024 Aug 12, 2024	BUY	$12.35 - $26.11 $37 - $78	3 Added 0.01%	55,877 $690,000
Q1 2024 Dec 26, 2024	BUY	$18.44 - $26.41 $359,967 - $515,549	19,521 Added 53.7%	55,874 $1.13 Million
Q1 2024 May 10, 2024	BUY	$18.44 - $26.41 $13,737 - $19,675	745 Added 1.35%	55,874 $1.13 Million
Q4 2023 Dec 26, 2024	BUY	$12.64 - $30.11 $237,328 - $565,345	18,776 Added 51.65%	55,129 $1.24 Million
Q4 2023 Feb 12, 2024	BUY	$12.64 - $30.11 $74,904 - $178,431	5,926 Added 12.04%	55,129 $1.24 Million
Q3 2023 Nov 14, 2023	SELL	$16.64 - $25.32 $106,778 - $162,478	-6,417 Reduced 11.54%	49,203 $818,000
Q2 2023 Aug 11, 2023	BUY	$21.59 - $27.88 $129,820 - $167,642	6,013 Added 12.12%	55,620 $1.36 Million
Q1 2023 May 18, 2023	BUY	$23.46 - $36.44 $1.14 Million - $1.76 Million	48,428 Added 4107.55%	49,607 $1.2 Million
Q1 2023 May 11, 2023	SELL	$23.46 - $36.44 $895,843 - $1.39 Million	-38,186 Reduced 97.0%	1,179 $28,000
Q4 2022 Feb 13, 2023	BUY	$27.82 - $44.16 $117,928 - $187,194	4,239 Added 12.07%	39,365 $1.16 Million
Q3 2022 Nov 14, 2022	SELL	$16.33 - $51.06 $338,684 - $1.06 Million	-20,740 Reduced 37.12%	35,126 $1.47 Million
Q2 2022 Aug 11, 2022	BUY	$17.22 - $38.47 $467,488 - $1.04 Million	27,148 Added 94.53%	55,866 $1.57 Million
Q1 2022 May 11, 2022	BUY	$32.6 - $53.05 $134,409 - $218,725	4,123 Added 16.76%	28,718 $1.07 Million
Q4 2021 Feb 10, 2022	BUY	$36.77 - $90.91 $56,846 - $140,546	1,546 Added 6.71%	24,595 $1.08 Million
Q3 2021 Nov 12, 2021	BUY	$41.79 - $135.3 $963,217 - $3.12 Million	23,049 New	23,049 $1.43 Million

Others Institutions Holding SAVA

# of Institutions

135

Shares Held

15.9M

Call Options Held

1.26M

Put Options Held

791K

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $111M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Cassava Sciences Inc Transaction History